Evidence map›Paper›PMID 36447978›Full record

ReviewIranian journal of public health2022

Turmeric for Treatment of Irritable Bowel Syndrome: A Systematic Review of Population-Based Evidence.

Emad Jafarzadeh, Shahram Shoeibi, Yaser Bahramvand, Elham Nasrollahi, Armin Salek Maghsoudi, Fatemeh Yazdi, Sepideh KarkonShayan, Shokoufeh Hassani

Open access · goldAbstract readReview
In one paragraph

Review in Iranian journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Observational
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Emad JafarzadehDepartment of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Shahram ShoeibiFood and Drug Laboratory Research Center, Iran Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.
Yaser BahramvandStudents' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Elham NasrollahiStudents' Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Armin Salek MaghsoudiDepartment of Toxicology and Pharmacology, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh YazdiDepartment of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Sepideh KarkonShayanStudent Research Committee, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran.
Shokoufeh HassaniToxicology and Diseases Group, Pharmaceutical Sciences Research Center, The Institute of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRShiraz University of Medical Sciences · IRGonabad University of Medical Sciences · IRIslamic Azad University, Science and Research Branch · IRMinistry of Health and Medical Education · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder of the gut interaction characterized by abdominal discomfort and pain associated with altered bowel habits in the absence of structural abnormalities. In spite of IBS' high prevalence and disease burden across the globe, no explanations have been given as to its underlying pathophysiology. As for the treatment of IBS, there is no specific medication, and the most beneficial treatment is usually supportive therapy. Recent animal and human studies have demonstrated the therapeutic potential of curcumin or turmeric in the treatment of IBS. Methods: We systematically reviewed all available evidence supporting curcumin and turmeric's therapeutic potential in relieving IBS symptoms in the present study. For this purpose, a database search was performed using curcumin, turmeric, and IBS and all their equivalents as of the search terms in Web of Science, Pub-Med, Scopus, Ovid, Embase, and Google Scholar from1990 up to Feb 2021. The investigation was then limited to clinical trials, and then nine articles were collected for data analysis. Results: The findings of the included literature showed that curcumin and turmeric alone or in combination with other medications could improve the severity of IBS as well as the quality of life among people who suffer from IBS symptoms. Conclusion: Overall, medications containing curcumin and turmeric extract due to these compounds' anti-inflammatory effects may improve IBS symptoms, particularly abdominal pain and life quality.

Indexed as

Curcuma longaCurcuminGastrointestinal disordersIrritable bowel syndromeTurmeric

Identifiers

PMID36447978
PMCPMC9659538
OpenAlexW4283073454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.